How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology

Cancer Treatment Reviews

Volumn 46, Issue , 2016, Pages 1-8

  Prescott, Lauren S ^a   Taylor, Jolyn S ^a   Lopez Olivo, Maria A ^a   Munsell, Mark F ^a   VonVille, Helena M ^b   Lairson, David R ^b   Bodurka, Diane C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anemia; Blood; Cancer; Neoplasms; Systematic review; Transfusion

Indexed keywords

ALLOANTIBODY; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADULT; ADVANCED CANCER; ALLERGIC URTICARIA; BLEEDING; BLOOD TRANSFUSION REACTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; HEART ARRHYTHMIA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INTERMETHOD COMPARISON; LIBERAL ALLOGENEIC PACKED RED BLOOD CELL TRANSFUSION; LUNG EDEMA; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NEUTROPENIA; ONCOLOGY; ORAL MUCOSITIS; PATIENT SAFETY; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTIVE ALLOGENEIC PACKED RED BLOOD CELL TRANSFUSION; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; SIDE EFFECT; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; NEOPLASMS; PROCEDURES; STANDARDS;

ERYTHROCYTE TRANSFUSION; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84961910344     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.03.010     Document Type: Review

References (47)

1. Foubert J. New EORTC guidelines for the treatment of anaemia in patients with cancer: implications for nursing practice. Eur J Oncol Nurs 2006, 10:177-186.
2. Ludwig H., Van Belle S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
3. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004, 116(Suppl. 7A):11S-26S.
4. Spivak J.L. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994, 21:3-8.
5. Altman A.D., Liu X.Q., Nelson G., Chu P., Nation J., Ghatage P. The effects of anemia and blood transfusion on patients with stage III-IV ovarian cancer. Int J Gynecol Cancer 2013, 23:1569-1576.
6. Beattie W.S., Karkouti K., Wijeysundera D.N., Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 2009, 110:574-581.
7. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91:2214-2221.
8. Dunst J., Kuhnt T., Strauss H.G., Krause U., Pelz T., Koelbl H., et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003, 56:778-787.
9. Evans J.C., Bergsjo P. The influence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology 1965, 84:709-717.
10. Shander A., Javidroozi M., Naqvi S., Aregbeyen O., Caylan M., Demir S., et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion. Transfusion 2014, 54:2688-2695.
11. Fyles A.W., Milosevic M., Pintilie M., Syed A., Hill R.P. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol 2000, 57:13-19.
12. Kim B.D., Ver Halen J.P., Mlodinow A.S., Kim J.Y. Intraoperative transfusion of packed red blood cells in microvascular free tissue transfer patients: assessment of 30-day morbidity using the NSQIP dataset. J Reconstr Microsurg 2014, 2:103-114.
13. Salpeter S.R., Buckley J.S., Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med 2014, 127:124-131.
14. Sun C., Wang Y., Yao H.S., Hu Z.Q. Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg 2015, 13:102-110.
15. Prescott L.S., Aloia T.A., Brown A.J., Taylor J.S., Munsell M.F., Sun C.C., et al. Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. Gynecol Oncol 2015, 136:65-70.
16. Luan H., Ye F., Wu L., Zhou Y., Jiang J. Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis. BMC Surg 2014, 14:34.
17. Acheson A.G., Brookes M.J., Spahn D.R. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012, 256:235-244.
18. Hebert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pagliarello G., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409-417.
19. Holst L.B., Haase N., Wetterslev J., Wernerman J., Guttormsen A.B., Karlsson S., et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014, 371:1381-1391.
20. Villanueva C., Colomo A., Bosch A., Concepcion M., Hernandez-Gea V., Aracil C., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013, 368:11-21.
21. Carson J.L., Grossman B.J., Kleinman S., Tinmouth A.T., Marques M.B., Fung M.K., et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012, 157:49-58.
22. Ferraris V.A., Brown J.R., Despotis G.J., Hammon J.W., Reece T.B., Saha S.P., et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Am Thorac Surg 2011, 91:944-982.
23. Qaseem A., Humphrey L.L., Fitterman N., Starkey M., Shekelle P. Clinical Guidelines Committee of the American College of P. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2013, 159:770-779.
24. Boone J.D., Kim K.H., Marques M., Straughn J.M. Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients. Gynecol Oncol 2014, 132:227-230.
25. Corwin H.L., Theus J.W., Cargile C.S., Lang N.P. Red blood cell transfusion: impact of an education program and a clinical guideline on transfusion practice. J Hosp Med 2014, 9:745-749.
26. Froman J.P., Mathiason M.A., Kallies K.J., Bottner W.A., Shapiro S.B. The impact of an integrated transfusion reduction initiative in patients undergoing resection for colorectal cancer. Am J Surg 2012, 204:944-950.
27. Wehry J., Cannon R., Scoggins C.R., Puffer L., McMasters K.M., Martin R.C.G. Restrictive blood transfusion protocol in liver resection patients reduces blood transfusions with no increase in patient morbidity. Am J Surg 2015, 210:1197-1205.
28. Goodnough L.T., Brecher M.E., Kanter M.H., AuBuchon J.P. Transfusion medicine - blood conservation. N Engl J Med 1999, 340:525-533.
29. Hofmann A., Ozawa S., Farrugia A., Farmer S.L., Shander A. Economic considerations on transfusion medicine and patient blood management. Best Pract Res Clin Anaesthesiol 2013, 27:59-68.
30. Lyman G.H., Berndt E.R., Kallich J.D., Erder M.H., Crown W.H., Long S.R., et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005, 8:149-156.
31. Cochrane Handbook For systematic Reviews of Interventions. In: Higgins J, Green S, editors; 2013.
32. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010, 8:336-341.
33. Vonville H. Reporting your systematic review methods & results. In: Prescott LS, editor 2014.
34. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
35. Sterne J, Higgins J, Reeves B. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI) 2014, ed2014.
36. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
37. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
38. Park S.H., Nam E., Bang S.M., Cho E.K., Shin D.B., Lee J.H. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer. Cancer Chemother Pharmacol 2008, 62:1-9.
39. Pinheiro de Almeida J., Vincent J.L., Barbosa Gomes Galas F.R., Marinho Pinto, de Almeida E., Fukushima J.T., et al. Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology 2015, 122:29-38.
40. Webert K.E., Cook R.J., Couban S., Carruthers J., Lee K.A., Blajchman M.A., et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008, 48:81-91.
41. Jansen A.J., Caljouw M.A., Hop W.C., van Rhenen D.J., Schipperus M.R. Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia. Transfus Med 2004, 14:33-38.
42. Carson J.L., Carless P.A., Hebert P.C. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012, 4:CD002042.
43. Carson J.L., Strair R. Transfusion strategies in hematologic and nonhematologic disease. Hematology Am Soc Hematol Educ Progr 2014, 2014:548-552.
44. Overgaard J., Hansen H.S., Overgaard M., Bastholt L., Berthelsen A., Specht L., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46:135-146.
45. Overgaard J., Hansen H.S., Specht L., Overgaard M., Grau C., Andersen E., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362:933-940.
46. Hoff C.M., Hansen H.S., Overgaard M., Grau C., Johansen J., Bentzen J., et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy-results from the randomized DAHANCA 5 study. Radiother Oncol 2011, 98:28-33.
47. Hoff C.M., Lassen P., Eriksen J.G., Hansen H.S., Specht L., Overgaard M., et al. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials. Acta Oncol 2011, 50:1006-1014.